CSL (OTCMKTS:CSLLY) vs. Trevi Therapeutics (NASDAQ:TRVI) Critical Comparison

Trevi Therapeutics (NASDAQ:TRVI) and CSL (OTCMKTS:CSLLY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations and price targets for Trevi Therapeutics and CSL, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	0	0	7	3	3.30
CSL	0	0	0	2	4.00

Trevi Therapeutics presently has a consensus target price of $15.94, suggesting a potential upside of 152.98%. Given Trevi Therapeutics’ higher probable upside, equities research analysts clearly believe Trevi Therapeutics is more favorable than CSL.

Earnings & Valuation

This table compares Trevi Therapeutics and CSL”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$29.07 million	($0.44)	-14.32
CSL	$14.80 billion	5.16	$2.64 billion	N/A	N/A

CSL has higher revenue and earnings than Trevi Therapeutics.

Insider and Institutional Ownership

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of CSL shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Trevi Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, CSL has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Profitability

This table compares Trevi Therapeutics and CSL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-63.31%	-57.06%
CSL	N/A	N/A	N/A

Summary

Trevi Therapeutics beats CSL on 6 of the 11 factors compared between the two stocks.

About Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.